Modeling and simulation for prediction of multiple sclerosis progression: A review and perspective
V Prathapan, P Eipert, N Wigger, M Kipp… - Computers in Biology …, 2024 - Elsevier
In light of extensive work that has created a wide range of techniques for predicting the
course of multiple sclerosis (MS) disease, this paper attempts to provide an overview of …
course of multiple sclerosis (MS) disease, this paper attempts to provide an overview of …
Markers of Secondary Progression in Multiple Sclerosis
A Bastos, M Soares, J Guimarães - Multiple Sclerosis and Related …, 2024 - Elsevier
Introduction There is no globally accepted definition of Secondary Progressive Multiple
Sclerosis (SPMS) or set of unambiguous clinical, radiological, or other criteria that can …
Sclerosis (SPMS) or set of unambiguous clinical, radiological, or other criteria that can …
The Impact of Sample Storage on Blood Methylation: Towards Assessing Myelin Gene Methylation as a Biomarker for Progressive Multiple Sclerosis
One of the major challenges in multiple sclerosis (MS) is to accurately monitor and quantify
disability over time. Thus, there is a pressing need to identify new biomarkers for disease …
disability over time. Thus, there is a pressing need to identify new biomarkers for disease …
Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression
Background: Multiple sclerosis (MS) is a prevalent chronic inflammatory and
neurodegenerative disease of the central nervous system. The main evolving forms …
neurodegenerative disease of the central nervous system. The main evolving forms …
Sociodemographic and Clinical Determinants of Fatigue in Multiple Sclerosis
Fatigue is the most common and disabling symptom in patients with multiple sclerosis
(PwMS), representing one of the main determinants of reduced quality of life among PwMS …
(PwMS), representing one of the main determinants of reduced quality of life among PwMS …
Promises of Lipid-Based Nanocarriers for Delivery of Dimethyl Fumarate to Multiple Sclerosis Brain
S Subhash, N Chaurawal, K Raza - Neuroprotection: Method and …, 2024 - Springer
Multiple sclerosis (MS) is a neurodegenerative autoimmune disorder of the central nervous
system (CNS) infecting 2.5 million people worldwide. It is the most common nontraumatic …
system (CNS) infecting 2.5 million people worldwide. It is the most common nontraumatic …
Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients
Background Multiple sclerosis (MS) is a debilitating neurological disease characterized by
inflammation, demyelination, and neurodegeneration in the central nervous system. Despite …
inflammation, demyelination, and neurodegeneration in the central nervous system. Despite …
Рассеянный склероз: современные диагностические маркеры и прогностические факторы прогрессирования
АИ Прокаева, ИЕ Архипов, ЕЕ Дорчинец… - Сибирский научный …, 2024 - sibmed.elpub.ru
Аннотация ассеянный склероз (РС) является одной из наиболее частых причин
инвалидизации лиц молодого трудоспособного возраста. Распространенность данного …
инвалидизации лиц молодого трудоспособного возраста. Распространенность данного …
Оптическая когерентная томография сетчатки как прогностический биомаркер прогрессирования рассеянного склероза
ТВ Щукина, ГН Бисага, ВА Малько… - Российский …, 2024 - rnj.com
Аннотация Рассеянный склероз (РС)—аутоиммунное воспалительно-
демиелинизирующее, нейродегенеративное инвалидизирующее заболевание …
демиелинизирующее, нейродегенеративное инвалидизирующее заболевание …